Application of a Dynamic Map for Learning, Communicating, Navigating, and Improving Therapeutic Development

Clinical and Translational Science

Volumn 11, Issue 2, 2018, Pages 166-174

  Wagner, John A ^a   Dahlem, Andrew M ^b   Hudson, Lynn D ^c   Terry, Sharon F ^d   Altman, Russ B ^e   Gilliland, C Taylor ^f   DeFeo, Christopher ^g   Austin, Christopher P ^f  

^a TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

^b ELI LILLY AND COMPANY   (United States)

^c CRITICAL PATH INSTITUTE   (United States)

^d GENETIC ALLIANCE   (United States)

^e STANFORD UNIVERSITY   (United States)

^f NATIONAL INSTITUTES OF HEALTH   (United States)

^g NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DORSOMORPHIN; MK 0557; NEUROPEPTIDE Y; NEUROPEPTIDE Y RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ARTICLE; DRUG DEVELOPMENT; DRUG POTENCY; DRUG TARGETING; ELECTRONIC MEDICAL RECORD; HUMAN; KIDNEY POLYCYSTIC DISEASE; NONHUMAN; OSSIFYING MYOSITIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; STUDY DESIGN; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL (TOPIC); FOOD AND DRUG ADMINISTRATION; INTERPERSONAL COMMUNICATION; INTERSECTORAL COLLABORATION; LEARNING; MEDICAL TECHNOLOGY; METABOLISM; METHODOLOGY; OBESITY; ORGANIZATION; PROCEDURES; TRANSLATIONAL RESEARCH; UNITED STATES;

BIOMEDICAL TECHNOLOGY; CLINICAL TRIALS AS TOPIC; COMMUNICATION; DRUG DEVELOPMENT; DRUG DISCOVERY; HUMANS; INTERSECTORAL COLLABORATION; LEARNING; MYOSITIS OSSIFICANS; NATIONAL ACADEMIES OF SCIENCE, ENGINEERING, AND MEDICINE (U.S.) HEALTH AND MEDICINE DIVISION; NEUROPEPTIDE Y; OBESITY; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT; PYRAZOLES; PYRIMIDINES; RESEARCH DESIGN; TRANSLATIONAL MEDICAL RESEARCH; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 85038814565     PISSN: 17528054     EISSN: 17528062     Source Type: Journal    
DOI: 10.1111/cts.12531     Document Type: Article

References (20)

1. Baxter, K. et al. An end to the myth: there is no drug development pipeline. Sci. Transl. Med. 5, 171cm1 (2013).
2. Navigating the Ecosystem of Translational Science. http://www.geneticalliance.org/programs/biotrust/nets/fullview.
3. The Drug Development Process. https://www.fda.gov/ForPatients/Approvals/Drugs/default.htm.
4. Pritchard, J.F., Jurima-Romet, M., Reimer, M.L., Mortimer, E., Rolfe, B. & Cayen, M.N. Making better drugs: decision gates in non-clinical drug development. Nat. Rev. Drug Discov. 2, 542–553 (2003).
5. Wagner, J. et al. A dynamic map for learning, communicating, navigating, and improving therapeutic development. Nat. Rev. Drug Disc. (2017). https://doi.org/10.1038/nrd.2017.217
6. Torres, V.E., Harris, P.C. & Pirson, Y. Autosomal dominant polycystic kidney disease. Lancet. 369, 1287–1301 (2007).
7. Perrone, R.D. et al. Therapeutic area data standards for autosomal dominant polycystic kidney disease: a report from the Polycystic Kidney Disease Outcomes Consortium (PKDOC). Am. J. Kidney Dis. 66, 583–590 (2015).
8. Perrone, R.D. et al. A drug development tool for trial enrichment in patients with autosomal dominant polycystic kidney disease. Kidney Int. Rep. 2, 451–460 (2017).
9. Perrone, R.D. et al. Total kidney volume is a prognostic biomarker of renal function decline and progression to end-stage renal disease in patients with autosomal dominant polycystic kidney disease. Kidney Int. Rep. 2, 442–450 (2017).
10. Food and Drug Administration. Qualification of biomarker—total kidney volume in studies for treatment of autosomal dominant polycystic kidney disease, guidance for industry.https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM458483.pdf (2016).
11. Yu, P.B. et al. Dorsomorphin inhibits BMP signals required for embryogenesis and iron metabolism. Nat. Chem. Biol. 4, 33–41 (2008).
12. Salazar, V.S., Gamer, L.W. & Rosen, V. BMP signalling in skeletal development, disease and repair. Nat. Rev. Endocrinol. 12, 203–221 (2016).
13. Cuny, G.D. et al. Structure-activity relationship study of bone morphogenetic protein (BMP) signaling inhibitors. Bioorg. Med. Chem. Lett. 18, 4388–4392 (2008).
14. Kaplan, F.S., Fiori, J.,de la Peña, L.S.,Ahn, J.,Billings, P.C. & Shore, E.M. Dysregulation of the BMP-4 signaling pathway in fibrodysplasia ossificans progressiva. Ann. NY Acad. Sci. 1068, 54–65 (2006).
15. Shore, E.M. & Kaplan, F.S. Insights from a rare genetic disorder of extra-skeletal bone formation, fibrodysplasia ossificans progressiva (FOP). Bone 43, 427–433 (2008).
16. Yu, P.B. et al. BMP type I receptor inhibition reduces heterotopic ossification. Nat. Med. 14, 1363–1369 (2008).
17. Erondu, N. et al. Neuropeptide Y5 receptor antagonism does not induce clinically meaningful weight loss in overweight and obese adults. Cell Metab. 4, 275–282 (2006).
18. Fichtner, M. et al. Discovery and evaluation of spirocyclic derivatives as antagonists of the neuropeptide Y5 receptor. Bioorg. Med. Chem. Lett. 22, 2738–2743 (2012).
19. Kealey, S. et al. Microfluidic reactions using [11C]carbon monoxide solutions for the synthesis of a positron emission tomography radiotracer. Org. Biomol. Chem. 9, 3313–3319 (2011).
20. Zhang, L., Bijker, M.S. & Herzog, H. The neuropeptide Y system: pathophysiological and therapeutic implications in obesity and cancer. Pharmacol. Ther. 131, 91–113 (2011).